404

Not Found

Is this what you were looking for?

index php buy viagra internet index php
By Jeffrey Bouley

Buying local

TheraCode acquires fellow German company JPT Peptide Technologies

Buy and build

Lab21 eyes international growth with Biotec Laboratories acquisition.
By Kimberely Sirk

Baxter’s buying

After dropping generic injectables, company adds hemophilia-related assets of Archemix to product stable
By Jeffrey Bouley

Elan Corp. to buy back $1 billion of stock after Tysabri sale

In addition, with the restructuring of the Tysabri collaboration with Biogen Idec, Elan will move from the current 50/50 business collaboration to an upfront payment of $3.25 billion and a double-digit tiered royalty structure for the life of the complete Tysabri asset
By Amy Swinderman

A la carte

French CRO Biotrial buys Bioanalytical Services division of Warnex
By Jeffrey Bouley

Northern momentum

After several buys in recent months already, Valeant doesn’t seem to be slowing down with the acquisitions, and the two newest-rumored names being bandied around both start with the same letter: Meda and Medicis
By Amy Swinderman

Merck and Schering-Plough to merge in $41.1 billion deal

WHITEHOUSE STATION, N.J.—Increasing generic competition and pricing pressures united two more of the world’s largest pharmaceutical players this week, as Merck & Co. announced on Monday it will buy Schering-Plough in a $41.1 billion stock-and-cash deal that some industry veterans are calling “the mating of dinosaurs.”

Run a Search

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue